Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528598 | 0.94 | ROCK2 (0.54) | ROCK2ROCK1CCR2 | |
| SCHEMBL659539 | 0.94 | ROCK2 (0.54) | ROCK2ROCK1CCR2 | |
| SCHEMBL1351433 | 0.89 | USP30 (0.55) | ROCK2ROCK1 | |
| SCHEMBL5662572 | 0.88 | ROCK2 (0.58) | ROCK2ROCK1CCR2 | |
| SCHEMBL29862650 | 0.88 | ROCK2 (0.58) | ROCK2ROCK1CCR2 | |
| SCHEMBL1509605 | 0.85 | ROCK2 (0.49) | ROCK2ROCK1CCR2 | |
| SCHEMBL5665496 | 0.84 | CYP2C9 (0.53) | ROCK2ROCK1 | |
| SCHEMBL1509653 | 0.84 | ROCK2 (0.48) | ROCK2ROCK1CCR2 | |
| SCHEMBL1509607 | 0.84 | ROCK2 (0.48) | ROCK2ROCK1CCR2 | |
| SCHEMBL29136079 | 0.82 | USP30 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723724-B2 | Compounds for treating degenerative diseases of central nervous system or brain tumor, and uses thereof | SUN YAT-SEN UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| US-20190202817-A1 | COMPOUNDS FOR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM OR BRAIN TUMOR, AND USES THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-2914590-B1 | NOVEL ROCK INHIBITORS | PH PHARMA CO LTD (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-9394286-B2 | Rock inhibitors | AMAKEM NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-20150299173-A1 | NOVEL ROCK INHIBTORS | AMAKEM NV (BE) | 2015-10-22 | — | — | US | disclosed |
| EP-2914590-A1 | NOVEL ROCK INHIBITORS | Amakem NV (BE) | 2015-09-09 | — | — | EP | disclosed |
| US-9073905-B2 | Rock inhibitors | AMAKEM NV (BE) | 2015-07-07 | — | — | US | disclosed |
| WO-2014068035-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2014-05-08 | — | — | WO | disclosed |
| EP-2702053-A2 | NOVEL ROCK INHIBITORS | Amakem NV (BE) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-7615564-B2 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-11-10 | — | — | US | disclosed |
| US-7615564-B2 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-11-10 | — | — | US | disclosed |
| US-7615564-B2 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-11-10 | — | — | US | disclosed |
| CN-100354264-C | 5-substituted isoquinoline derivatives and drugs containing them | ASAHI KASEI PHARMA CORP (JP) | 2007-12-12 | — | — | CN | disclosed |
| US-7094789-B2 | 5-substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20060167043-A1 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1668600-A | 5-substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORP (JP) | 2005-09-14 | — | — | CN | disclosed |
| EP-1550660-A1 | ISOQUINOLINE DERIVATIVES HAVING KINASAE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1541559-A1 | 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885CCR2 1525/4885 |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | MYLK, MYLK2, MYL12A | ROCK2 158/4885ROCK1 75/4885CCR2 3138/4885 |
| US-20060167043-A1 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same | ROCK2, MAP4K5, TNK2 | ROCK2 1/4885ROCK1 5/4885CCR2 2249/4885 |
| US-20150299173-A1 | NOVEL ROCK INHIBTORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885CCR2 2141/4885 |
| US-20190202817-A1 | COMPOUNDS FOR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM OR BRAIN TUMOR, AND USES THEREOF | SGK1, SGK3, SGK2 | ROCK2 515/4885ROCK1 457/4885CCR2 2360/4885 |
| US-10723724-B2 | Compounds for treating degenerative diseases of central nervous system or brain tumor, and uses thereof | SGK1, SGK3, SGK2 | ROCK2 515/4885ROCK1 457/4885CCR2 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.